total revenue vs non-gaap ep vs ahead
consensu hiv hcv revenu less in-lin revenu upsid come
letairi gilead hiv franchis continu perform biktarvi launch pace
best yet hope gilead trough earn pass remain
outperform price target unchang
world-wide hiv sale q/q y/i in-lin consensu
hcv/hbv sale q/q y/i
consensu letairi revenu
well ahead consensu gener yet launch
 follow juli loe total revenu q/q y/i beat
estim consensu gilead report non-gaap gross margin
vs non-gaap sg expens revenu
revenu vs respect gilead
report tax rate vs non-gaap ep q/q y/i
consensu full year non-gaap effect tax
rate gilead lower guidanc guidanc net product
sale increas increas product sale
estim increas non-gaap ep estim
dcf-base price target remain
hiv sale q/q y/i in-lin consensu
 hiv revenu q/q y/i grow robustli
continu benefit biktarvi launch biktarvi revenu
second full quarter market put pace best yet hiv gilead
report biktarvi number one prescrib regimen treatment-na
switch patient demand larg driven switch regimen
includ switch patient dolutegravir regimen
switch genvoya patient consult suggest biktarvi
go-to regimen especi treatment newly-diagnos patient demand trend
gilead franchis overal remain healthi prescript q/q gilead
report taf-bas regimen account gilead hiv prescript volum
 slightli end normal payor mix
gilead hiv franchis consist commerci govern howev
mix shift even split commerci govern mix
maintain
sale intern market q/q y/i impact launch
truvada gener sever european countri summer holiday gilead note
impact gener less initi anticip particularli itali
 biktarvi approv eu june launch well germani
gilead expect launch biktarvi addit european countri help off-set
impact gener
pleas see page report import disclosur
gilead market leader treatment hiv hcv acquir car-t
oncolog platform kite expect combin launch
new taf-bas combin pill hiv market growth share gain price increas
hiv franchis sale grow compound-annual-growth-rate despit viread
patent expir gilead hcv franchis struggl declin patient volum
new competit erod sale project gilead hcv franchis gener
world-wide sale declin expect partial off-set pipelin
program includ yescarta filgotinib base dcf analysi gilead stock
under-valued expect cash flow
data ph ii studi fxr agonist
nash psc aasld
two-year follow data
data ph ii studi
tirabrutinib r/r cll
hcv sale
hiv franchis grow
despit expir
rest pipelin product
exce project
launch taf-bas pill allow
hiv franchis grow
expir tenofovir patent
candid pipelin
hcv sale fail achiev forecast
hiv franchis fail meet
project due competit major
chang treatment paradigm
gilead pipelin busi
develop effort fail produc
product capabl drive meaning
revenu earn
gilead develop market treatment hiv hbv hcv fungal infect
acquir car-t oncolog platform kite gilead antivir portfolio biggest
revenu driver gilead lead hiv franchis anchor tenofovir well-toler
efficaci nucleotid analog gilead develop sever tenofovir-bas
biktarvi togeth captur share treatment-na hiv patient
drive hiv franchis revenu project revenu
hcv franchis led sofosbuvir nucleosid inhibitor result phase trial
sofosbuvir-bas regimen shown potent well toler high
barrier viral resist expect hcv franchis maintain revenu
hcv patient start continu declin price market share larg stabl
 hcv revenu q/q y/i ex-u hcv revenu
q/q y/i declin global declin q/q acceler compar
q/q manag note price market share larg stabil
declin revenu due mostli fewer patient begin therapi
manag remain hope stabl predict busi go forward
price share consist slow steadi declin hcv market patient start
reduc hcv estim septemb gilead
announc newli launch subsidiari begin offer
author gener epclusa harvoni januari gilead expect gener
reduc patient cost expand access
letairi sale quarter versu consensu letairi lost
exclus juli gener launch gilead believ order gener
launch fda need approv singl share rem program yet happen
pdufa date limit visibl could gilead therefor
expect letairi sale continu approxim current rate end
year caution sale uncertain
gilead record q/q revenu yescarta third full quarter
market slightli consensu estim
cancer center author treat patient new center continu
author manag indic focu shift increas patient
flow part via educ effort commun oncologist direct patient
author center gilead note variabl volum across center
experienc earli adopt drive major use center still work
busi model incorpor yescarta includ gain reimburs
medicar patient gilead anticip adopt gradual improv center gain
experi
yescarta approv eu august gilead plan author center
year end initi focu launch germani franc anticip
european approv yescarta gilead previous leas manufactur facil
netherland come on-lin
clinic trial yescarta continu pivot phase studi line dlbcl
phase ii studi combin initi pivot
phase ii yescarta r/r indol nhl set complet enrol
addit gilead expect complet enrol pivot ph ii formerli kte-
construct yescarta differ manufactur mcl
initi pivot phase ii pediatr pivot phase ii
adult recruit
gilead also highlight recent progress pipelin develop inflamm sever
phase studi filgotinib on-going rheumatoid arthriti ulcer coliti
crohn diseas filgotinib succeed phase finch trial ra patient
inadequ respons dmard addit phase trial ra
fulli enrol data readout expect phase ii
studi filgotinib sever inflammatori diseas also on-going
result selonsertib stellar stellar phase nash
anticip respect gilead expect studi
posit file regulatori approv success could first
bring product nash market gilead also plan releas data descovi phase
discov trial hiv prophylaxi
investor wait gilead revenu stabil two year declin
despit continu hcv contract model suggest revenu trough may
reach gilead hcv franchis declin sinc hcv revenu
becom rel minor part gilead top-lin launch
taf regimen gilead hiv franchis continu bright spot biktarvi
earli launch suggest help gilead regain share dolutegravir regimen
 prescript q/q model project hiv revenu growth
off-set declin hcv letairi ranexa anticip next year y/
total revenu growth far excit suggest gilead fundament may
turn corner continu believ gilead under-valued cash flow
gilead develop market treatment hiv hbv hcv fungal infect
gilead antivir portfolio largest revenu driver next sever
year gilead lead hiv franchis anchor tenofovir well-toler
gener revenu captur share patient newli initi
hiv therapi tenofovir disoproxil fumar viread lost patent
protect gilead develop second gener version tenofovir
alafenamid taf improv safeti extend patent protect
project sale gilead hiv franchis grow
launch new patent-protect combin pill biktarvi bic/f/taf
genvoya e/c/f/taf descovi f/taf odefsey e/r/taf taf
regimen extend commerci life franchis howev expiri
 patent protect truvada complera model hiv sale
declin y/i gilead hcv franchis built around
sovaldi nucleosid inhibitor whose potenc high barrier resist
made cornerston market-lead all-or hcv combin sovaldi
launch decemb eu januari approv
gilead harvoni sofosbuvir ledispavir octob brought first
fda-approv interferon free regimen genotyp hcv patient largest
hcv popul hcv franchis got fast start post
revenu unfortun best day gilead hcv
franchis past emerg competit gild hcv franchis
gener revenu estim continu declin
gilead recent expand oncolog franchis
acquisit kite gilead gain yescarta car-t therapi anhl
approv fda octob well lead car-t
platform cowen project yescarta achiev revenu third line anhl
hope gilead trough earn final sight
two year rapid declin hcv revenu project non-gaap ep
non-gaap ep grow compound-annual-growth-rate
gilead current trade forward pe project cash
flow yield base dcf analysi gilead stock under-valued
initi phase ib studi capsid inhibitor
data phase ii studi fxr agonist nash psc
data phase ii studi fxr agonist pbc
year follow-up data zuma
complet enrol phase ii yescarta r/r indol nhl zuma
initi phase yescarta combo zuma
initi pivot phase ii ped zuma
complet enrol phase ii mcl zuma
initi phase cll zuma
complet enrol phase ia studi anti-bcma mm
decis registr studi anti-bcma base phase data
file ind tcr target solid tumor
phase ii data tirabrutinib idelalisib entospletinib r/r cll
complet enrol phase select studi filgotinib ulcer coliti
data phase data selonsertib nash stellar
data filgotinib finch studi ra
data filgotinib finch studi ra
data phase ii studi nrti
primari endpoint data phase discov trial descovi prep
data phase studi selonsertib nash stellar
data phase ii cutan lupu erythematosu
data phase ii sjogern syndrom
complet phase ii remdesivir ebola
complet phase studi vesatolimod hiv cure
complet enrol filgotinib divers studi crohn diseas
complet enrol phase line dlbcl zuma
complet enrol ph ia mage solid tumor
data phase iib atla combin studi nash
cowen compani
cowen compani
total hiv total hcv ranexa product contract comp in-process acquisit cost total sale asset interest net income/ loss incom loss attribut non-controlling net fa net income/ loss ex fa forma ep ex fa share cowen
cowen compani
total hiv total hcv ranexa duct contract incom loss attribut non-controlling fa income/ loss ex fa forma ep ex fa share cowen
statement flow mm
cowen compani
depreci amort stock comp tax benefit employe stock chang net work capit ex cash provid use oper purchas /sale/matur market capit issuanc note acquisit net cash cash provid use invest proce issuanc of/ repurchas common proce issuanc of/ repurchas payment cash provid financ exchang rate chang increas decreas cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
cowen compani
financi year growth growth growth ranexa contract tax asset utilizedtax ratetax payment debtapprox free year growth ratetermin valu termin valu balanc dilut share per fulli dilut valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
gilead develop commerci drug number indic includ hiv hcv
hbv influenza cancer pulmonari hypertens forecast sale product
difficult outlook could alter new safety/efficaci find emerg
competit alter medic treatment paradigm chang pricing/
reimburs environ gilead stock price could also impact chang
outlook key pipelin program evalu market potenti drug
yet approv particularli riski moreov market exclus
gilead franchis depend patent subject challeng gener
drugmak valu gilead franchis could diminish lose
protect key patent
